2. Antibody-drug Conjugate/ADC Related Cytoskeleton Cell Cycle/DNA Damage Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Apoptosis
  4. Atezolizumab-MMAE

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model.

For research use only. We do not sell to patients.

Atezolizumab-MMAE Chemical Structure

Atezolizumab-MMAE Chemical Structure

Size Price Stock Quantity
500 μg In-stock
1 mg In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Atezolizumab-MMAE Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model[1][2].

In Vitro

Atezolizumab-MMAE (Compound 3) (4 µg/mL, 0.5-24 h) can bind to the PD-L1 antigen on the cells membrane and be internalized and transported to lysosomes within 30 min in MDA-MB-231 cells[1].
Atezolizumab-MMAE (0.725-200000 pmol/L, 3 days) has a potent tumor cell inhibitory activity (EC50 of 10.33, 9.75 and 11.94 nM for PD-L1 + MDA-MB-231, PC 9 and A431 cells, respectively) while a weak effect on PD-L1 - Romas cells (EC50: 129.4 nM)[1].
Atezolizumab-MMAE (0.625-10 μg/mL, 48 h) mediates inhibition of the PD1 and PD-L1 interaction and significantly increases levels of IFN-γ when co-cultures with PBMCs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Atezolizumab-MMAE Related Antibodies

Cell Viability Assay[1]

Cell Line: MDA-MB-231, PC 9, A431, Romas cells
Concentration: 0.725-200000 pmol/L
Incubation Time: 3 days
Result: Demonstrated a potent inhibitory activity in the MDA-MB-231, PC 9 and A431 PD-L1 + cell lines with EC50 of 10.33 nM, 9.75 nM, and 11.94 nM, respectively.
Exhibited a weak inhibitory activity against the PD-L1 - cell Romas lines with EC50 of 124.9 nM.

Cell Viability Assay[1]

Cell Line: MDA-MB-231 cells
Concentration: 4 µg/mL
Incubation Time: 0, 0.5, 1, 4, 18, 24 h
Result: Could bind to the PD-L1 antigen on the membrane of MDA-MB-231 cells at 4 °C.
Be internalized into lysosomes of MDA-MB-231 cells only 30 min.
In Vivo

Atezolizumab-MMAE (Compound 3) (3 mg/kg, i.p., 2 times per week for 3  weeks) has a potent anti-tumor effect (68% tumor inhibition and 60% tumor regression) compared to Atezolizumab alone in MC38 xenograft PD-1-humanized immune system mice model [1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C57BL/6J-Pdcd1em1 (hPDCD1)/Smoc mice (6-8 weeks old) were inoculated subcutaneously into the upper groin of the lateral hind limbs with log growth-phase of MC38 cells (1 × 106 cells/mouse)[1].
Dosage: 3 mg/kg
Administration: i.p., 2 times per week for 3  weeks following tumor volume reaching about 50-150 mm3, and then measured tumor volume and body weights twice weekly.
Result: Produced significant and sustained antitumor effects with a 68% tumor inhibition rate.
Significantly disappeared tumor with tumor regression of 60%, which higher than Atezolizumab alone (tumor regression: 40%).
Had a safety profile with no significant body weight changes.
Appearance

Liquid

SMILES

[Atezolizumab-MMAE]
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Atezolizumab-MMAE Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Atezolizumab-MMAEAntibody-Drug Conjugates (ADCs)Microtubule/TubulinApoptosisAntibody-Drug ConjugatesPD-L1Antibody-drug conjugateADCAntitumorCancer therapyImmunotherapyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Atezolizumab-MMAE
Cat. No.:
HY-171572
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.